<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332797</url>
  </required_header>
  <id_info>
    <org_study_id>GO39932</org_study_id>
    <secondary_id>2017-002083-41</secondary_id>
    <nct_id>NCT03332797</nct_id>
  </id_info>
  <brief_title>A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer</brief_title>
  <official_title>A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and
      preliminary anti-tumor activity of GDC-9545 as a single agent and in combination with
      palbociclib and/or luteinizing hormoneâˆ’releasing hormone (LHRH) agonist in patients with
      advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor
      receptor 2 [HER2]-negative) breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>From baseline through end of study (up to 21 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of GDC-9545 When Used as a Single Agent</measure>
    <time_frame>Days -7 to 28 of Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of GDC-9545 Administered as a Single Agent</measure>
    <time_frame>At predefined intervals from Cycle 1, Day -7 through Cycle 4, Day 1 (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of GDC-9545 Administered in Combination</measure>
    <time_frame>At predefined intervals from Cycle 1, Day 1 through Cycle 4, Day 1 (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response</measure>
    <time_frame>Baseline; Every 8 weeks from Cycle 1, Day 1 to end of study (up to 21 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate Assessed by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v 1.1)</measure>
    <time_frame>From baseline to end of study (up to 21 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From the first occurrence of a documented objective response to the first observation of disease progression or death from any cause through the end of study (up to 21 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Palbociclib</measure>
    <time_frame>At predefined intervals from Cycle 1, Day 1 through Cycle 4, Day 1 (4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of LHRH</measure>
    <time_frame>At predefined intervals from Cycle 1, Day 1 through Cycle 4, Day 1 (4 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation: GDC-9545</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During dose escalation, participants will be assigned sequentially to escalating doses of GDC-9545, up to the maximum tolerated dose (MTD) or maximum administered dose (MAD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: Cohort B0: GDC-9545 + Palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC-9545 will be administered at a dose lower than the MTD or MAD determined in single-agent dose escalation along with the label-recommended dose of Palbociclib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort A1: GDC-9545 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC-9545 will be administered as a single-agent at a dose lower than the MTD/MAD (Dose 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort A2: GDC-9545 Dose 1 + LHRH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC-9545 will be administered at a dose lower than the MTD or MAD (Dose 1) along with an approved LHRH agonist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort A3: GDC-9545 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC-9545 (Dose 2) will be administered as a single-agent at a dose at or below the MTD/MAD and above Dose 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort A4; GDC-9545 Dose 2 + LHRH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC-9545 will be administered at Dose 2 along with an LHRH agonist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort B1: GDC-9545 + Palbociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC-9545 will be administered at a dose that is at or below MTD/MAD along with Palbociclib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC-9545 will be administered at or below MTD/MAD along with Palbociclib and an approved LHRH-agonist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-9545</intervention_name>
    <description>GDC-9545 will be administered orally, once daily, on Days 1-28 of a 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination (approximately 21 months).</description>
    <arm_group_label>Dose Escalation: GDC-9545</arm_group_label>
    <arm_group_label>Dose Escalation: Cohort B0: GDC-9545 + Palbociclib</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort A1: GDC-9545 Dose 1</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort A2: GDC-9545 Dose 1 + LHRH</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort A3: GDC-9545 Dose 2</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort A4; GDC-9545 Dose 2 + LHRH</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort B1: GDC-9545 + Palbociclib</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib will be administered orally, once daily, at the label-recommended dose of 125mg on Days 1-21 of a 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination (approximately 21 months).</description>
    <arm_group_label>Dose Escalation: Cohort B0: GDC-9545 + Palbociclib</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort B1: GDC-9545 + Palbociclib</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHRH agonist</intervention_name>
    <description>LHRH agonist will be administered by injection once every 4 weeks from Day 1, Cycle 1, of a 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination (approximately 21 months). Physician will choose LHRH agonist approved for use in breast cancer.</description>
    <arm_group_label>Dose Expansion: Cohort A2: GDC-9545 Dose 1 + LHRH</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort A4; GDC-9545 Dose 2 + LHRH</arm_group_label>
    <arm_group_label>Dose Expansion: Cohort B2: GDC-9545 + Palbociclib + LHRH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Dose Escalation:

          -  Histologically or cytologically proven diagnosis of adenocarcinoma of the breast with
             evidence of either locally recurrent disease not amenable to resection or radiation
             therapy with curative intent or with metastatic disease

          -  ER-positive tumor

          -  HER2-negative breast cancer as per local laboratory testing

          -  Measurable disease, or evaluable bone disease; that is, bone lesions that are lytic or
             mixed (lytic + sclerotic) in the absence of measurable lesion

          -  Required paired pre- and on-treatment tumor biopsies for participants with metastases
             that are safely accessible as determined by the investigator

          -  Advanced or metastatic ER-positive/HER2-negative breast cancer that has recurred or
             progressed while being treated with adjuvant endocrine therapy for a duration of at
             least 24 months and/or endocrine therapy in the incurable, locally advanced, or
             metastatic setting and derived a clinical benefit from therapy (i.e., tumor response
             or stable disease for at least 6 months)

          -  No more than 2 prior lines of treatment for advanced or metastatic breast cancer

          -  â‰¥ 2 weeks must have elapsed from the use of any other endocrine, targeted therapy or
             chemotherapy

          -  Cohort B0: No prior treatment with Cyclin-Dependent Kinase (CDK) 4/6 inhibitor

          -  For participants undergoing 18F-fluoroestradiol (FES) positron emission tomography
             (PET) imaging additional restrictions on prior therapy include: â‰¥ 2 months must have
             elapsed from the use of tamoxifen; â‰¥ 6 months must have elapsed from the use of
             fulvestrant

          -  Postmenopausal status

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status â‰¤ 1

          -  Resolution of all acute toxic effects of prior therapy or surgical procedures to
             baseline or Grade â‰¤ 1 (except alopecia or other toxicities not considered to be a
             safety risk for the patient)

          -  Life expectancy of â‰¥ 12 weeks

          -  Adequate organ function

        Inclusion Criteria for Dose Expansion:

        Same as above, except:

          -  No more than one prior line of treatment for advanced or metastatic breast cancer

          -  Advanced or metastatic disease that is either refractory to or intolerant of existing
             standard therapy or for which no effective standard therapy that confers clinical
             benefit is available

        And plus:

          -  Cohort B1âˆ’2: No prior treatment with CDK4/6 inhibitor

          -  Cohorts A1, A3, and B1 only: Postmenopausal status

          -  Cohorts A2, A4, and B2 only: Participants not defined as post-menopausal

          -  No prior treatment with an oral selective estrogen receptor degrader (SERD)

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use non-hormonal contraceptive methods with a failure
             rate of &lt; 1% per year during the treatment period and for 40 days after the last dose
             of GDC-9545

        Exclusion Criteria for Dose Escalation:

          -  Known brain metastases that are untreated, symptomatic, or require therapy to control
             symptoms.

          -  Current treatment with any systemic anti-cancer therapies for advanced disease

          -  Concurrent treatment with warfarin or phenytoin

          -  Diagnosis of any secondary malignancy within 3 years prior to enrollment, except for
             appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or
             Stage I uterine cancer

          -  Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major
             upper GI surgery including gastric resection

          -  Known Human Immunodeficiency Virus (HIV) infection

          -  Known clinically significant history of liver disease consistent with Child-Pugh Class
             B or C, including active viral or other hepatitis (e.g., hepatitis B or hepatitis C
             virus), current alcohol abuse, or cirrhosis

          -  Major surgery within 4 weeks prior to enrollment

          -  Radiation therapy within 2 weeks prior to enrollment

        Exclusion Criteria for Dose Expansion:

        Same as above, plus:

          -  Pregnant, lactating, or breastfeeding

          -  Additional exclusion criteria for participants in Cohort B: History of venous
             thromboembolic event requiring therapeutic anticoagulation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO39932 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center; Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Maccallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center; Medical Oncology</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO L'Hospitalet; Servicio de oncologia medica</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron Barcelona; Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario RamÃ³n y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro; South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E1 2ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust; Oncology</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

